Research Analysts’ Weekly Ratings Changes for Hikma Pharmaceuticals (HIK)

A number of research firms have changed their ratings and price targets for Hikma Pharmaceuticals (LON: HIK):

  • 11/20/2018 – Hikma Pharmaceuticals had its price target raised by analysts at JPMorgan Chase & Co. from GBX 1,050 ($13.72) to GBX 1,900 ($24.83). They now have a “neutral” rating on the stock.
  • 11/12/2018 – Hikma Pharmaceuticals was downgraded by analysts at Peel Hunt to a “hold” rating. They now have a GBX 2,000 ($26.13) price target on the stock, up previously from GBX 1,950 ($25.48).
  • 11/9/2018 – Hikma Pharmaceuticals had its “equal weight” rating reaffirmed by analysts at Barclays PLC. They now have a GBX 1,950 ($25.48) price target on the stock.
  • 11/8/2018 – Hikma Pharmaceuticals had its “add” rating reaffirmed by analysts at Peel Hunt.
  • 11/6/2018 – Hikma Pharmaceuticals was upgraded by analysts at Barclays PLC to an “equal weight” rating. They now have a GBX 1,800 ($23.52) price target on the stock, up previously from GBX 1,400 ($18.29).
  • 11/1/2018 – Hikma Pharmaceuticals had its “add” rating reaffirmed by analysts at Peel Hunt.
  • 10/30/2018 – Hikma Pharmaceuticals had its “buy” rating reaffirmed by analysts at Citigroup Inc. They now have a GBX 2,250 ($29.40) price target on the stock.
  • 10/23/2018 – Hikma Pharmaceuticals had its “add” rating reaffirmed by analysts at Peel Hunt.
  • 10/15/2018 – Hikma Pharmaceuticals had its “underweight” rating reaffirmed by analysts at Barclays PLC.
  • 10/9/2018 – Hikma Pharmaceuticals had its “underweight” rating reaffirmed by analysts at Barclays PLC.
  • 10/3/2018 – Hikma Pharmaceuticals had its price target raised by analysts at Citigroup Inc from GBX 2,100 ($27.44) to GBX 2,250 ($29.40). They now have a “buy” rating on the stock.
  • 10/3/2018 – Hikma Pharmaceuticals had its “add” rating reaffirmed by analysts at Peel Hunt.
  • 9/24/2018 – Hikma Pharmaceuticals had its “underweight” rating reaffirmed by analysts at Barclays PLC.

Shares of HIK stock traded up GBX 30 ($0.39) during trading hours on Friday, reaching GBX 1,691.50 ($22.10). The company had a trading volume of 259,830 shares, compared to its average volume of 822,138. Hikma Pharmaceuticals Plc has a 12-month low of GBX 814.20 ($10.64) and a 12-month high of GBX 2,346 ($30.65).

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.

Further Reading: Balance Sheet

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply